New immunosuppressive agents in pediatric transplantation

被引：13

作者：

Christina Nguyen ^{[1
]}

Shapiro, Ron ^{[2
]}

机构：

[1] UPMC, Childrens Hosp Pittsburgh, Div Pediat Nephrol, Pittsburgh, PA 15219 USA

[2] UPMC, Thomas E Starzl Transplantat Inst, Div Transplant Surg, Pittsburgh, PA USA

来源：

CLINICS | 2014年 / 69卷

关键词：

Transplantation; Pediatric Transplantation; Immunosuppression; DOSE CYCLOSPORINE MONOTHERAPY; HEMOLYTIC-UREMIC SYNDROME; IMPROVED RENAL-FUNCTION; MYCOPHENOLATE-MOFETIL; CALCINEURIN INHIBITOR; LIVER-TRANSPLANTATION; KIDNEY-TRANSPLANTATION; MULTICENTER TRIAL; RANDOMIZED-TRIAL; CAMPATH; 1H;

D O I：

10.6061/clinics/2014(Sup01)03

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immunosuppressive therapy in pediatrics continues to evolve. Over the past decade, newer immunosuppressive agents have been introduced into adult and pediatric transplant patients with the goal of improving patient and allograft survival. Unfortunately, large-scale randomized clinical trials are not commonly performed in children. The purpose of this review is to discuss the newer immunosuppressive agents available for induction therapy, maintenance immunosuppression, and the treatment of rejection.

引用

页码：8 / 16

页数：9

共 73 条

[1] Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation [J].

Al-Akash, Samhar I. ;

Almond, P. Stephen ;

Savell, Van H., Jr. ;

Gharaybeh, Salam I. ;

Hogue, Cris .

PEDIATRIC NEPHROLOGY, 2011, 26 (04) :613-619

[2] Tasocitinib [J].

不详 .

Drugs in R & D, 2010, 10 (4) :271-284

[3] Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation [J].

Arora, Swati ;

Tangirala, Bhargavi ;

Osadchuk, Liliana ;

Sureshkumar, Kalathil K. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (07) :965-979

[4] Campath-1H use in pediatric renal transplantation [J].

Bartosh, SM ;

Knechtle, SJ ;

Sollinger, HW .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) :1569-1573

[5] Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus [J].

Behnke-Hall, Kachina ;

Bauer, Juergen ;

Thul, Josef ;

Akintuerk, Hakan ;

Reitz, Katharina ;

Bauer, Anna ;

Schranz, Dietmar .

PEDIATRIC TRANSPLANTATION, 2011, 15 (08) :784-789

[6] Liver regeneration is impaired by FK778 in partially hepatectomized rats, while supplemental uridine restores both liver growth and hepatocyte proliferation [J].

Biglarnia, Ali-Reza ;

Lorant, Tomas ;

Lee, Hyon-Soek ;

Tufveson, Gunnar ;

Toetsch, Martin .

HEPATOLOGY RESEARCH, 2009, 39 (01) :86-92

[7] Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat [J].

Bilolo, KK ;

Ouyang, J ;

Wang, X ;

Zhu, SY ;

Jiang, WL ;

Qi, SJ ;

Xu, DS ;

Hebert, MJ ;

Bekersky, I ;

Fitzsimmons, WE ;

Chen, HF .

TRANSPLANTATION, 2003, 75 (11) :1881-1887

[8] Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients [J].

Boratynska, M ;

Banasik, M ;

Watorek, E ;

Falkiewicz, K ;

Patrzalek, D ;

Szyber, P ;

Klinger, M .

TRANSPLANTATION PROCEEDINGS, 2006, 38 (01) :101-104

[9]

Bristol-Myers Squibb, 2013, NUL HIGHL PRESCR INF

[10] Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients [J].

Calne, R ;

Moffatt, SD ;

Friend, PJ ;

Jamieson, NV ;

Bradley, JA ;

Hale, G ;

Firth, J ;

Bradley, J ;

Smith, KGC ;

Waldmann, M .

TRANSPLANTATION, 1999, 68 (10) :1613-1616

← 1 2 3 4 5 6 7 8 →